PFE PFE ファイザ―

 PFEのチャート


 PFEの企業情報

symbol PFE
会社名 Pfizer Inc (PFE ファイザ―)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 ファイザー(Pfizer Inc.)は研究ベースのグローバルなバイオ医薬品会社である。同社は医療製品の発見、開発、製造に従事する。グローバル・ポートフォリオには医薬品とワクチン、消費者向けの医療製品が含まれる。同社はファイザー・イノベーティブ・ヘルス(IH)とファイザー・エッセンシャル・ヘルス(EH)という2つの事業区分を通じて商業活動を管理する。IH事業は医薬品とワクチン、消費者向けのヘルスケア製品の開発と商業化を行う。IHの治療分野は内科、ワクチン、腫瘍学、炎症、免疫学、希少疾患と消費者医療を含む。EH事業にはレガシー・ブランド、ブランド・ジェネリック、一般的無菌注射用製品、バイオシミラーと輸液システムを含む他、研究・開発(R&D)組織と契約製造事業を含む。ブランドは「Prevnar 13」、「Xeljanz」、「Eliquis」、「Lipitor」、「Celebrex」、「Pristiq」、「Viagra」を含む。  ファイザ―は米国大手医薬品メ―カ―。循環器系、中枢神経系、鎮痛・抗炎症系、筋骨格系、感染症、泌尿器系、眼科系、ガン、内分泌系、ワクチンの薬剤を開発、製造、販売。主要製品は「セレブレックス」、「チャンテックス」、「リピト―ル」、「リリカ」、「プリスティ―ク」、「バイアグラ」。抗感染、内分泌傷害、血友病、炎症、多発性硬化症の医薬品も展開。  Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
本社所在地 235 East 42nd Street New York NY 10017 USA
代表者氏名 Ian C. Read
代表者役職名 Executive Chairman of the Board
電話番号 +1 212-573-2323
設立年月日 15493
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 92400人
url www.pfizer.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 23035.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 235785.20000
売上高 売上高(百万ドル) 53647.00000
企業価値(EV) 企業価値(EV)(百万ドル) 258711.20000
当期純利益 当期純利益(百万ドル) 10347.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Pfizer Inc. revenues increased 2% to $53.65B. Net income applicable to common stockholders excluding extraordinary items decreased 13% to $10.35B. Revenues reflect Operating Segment-Global Innovative Pharmaceutical increase of 6% to $33.43B Emerging Markets segment increase of 11% to $12.65B Developed Europe segment increase of 7% to $9.12B. Net income was offset by Impairment of Intangibles excl.

 PFEのテクニカル分析


 PFEのニュース

   Lipid Injectable Drugs Market With Leading Players like Fresenius Kabi, Abbott Laboratories, Pfizer, B. Braun Melsungen AG, Baxter International, Heron Therapeutics, Novartis AG, ACON Laboratories, CordenPharma International, Boehringer Ingelheim Pharma G  2020/11/13 05:41:30 OpenPR
Lipid injectable has been clinically used as an energy source that provides essential fatty acids and vitamins to hospitalized patients. Lipid emulsions are also used for delivering lipid-soluble therapeutic agents intravenously, owing to the biocompatible nature of the lipid-based delivery
   Oil falls on COVID-19 surge but on track for weekly gain  2020/11/13 04:25:32 The Sun Daily
TOKYO: Oil prices fell on Friday, pressured by fears about a slow recovery in the global economy and fuel demand due to an accelerating rise in COVID-19 infections, but remained on track for a second straight weekly gain, helped by vaccine hopes. Brent crude was down 75 cents, or 1.7%, at $42.78 a barrel as of 0314 GMT, after dropping 0.6% on Thursday. U.S. West Texas Intermediate (WTI) crude futures fell 89 cents, or 2.2%, to $40.23 a barrel, having lost 0.8% on Thursday. For the week, both were headed for a surge of about 8%. U.S. government data also added pressure, as crude inventories rose by 4.3 million barrels last week, compared with an expected fall of 913,000 barrels. "Investors took profits from the recent rally as a gloomy global economic outlook dampened sentiment amid a sharp increase in coronavirus cases and new social restrictions," said Koichi Murakami, an analyst at Daiichi Commodities Co Ltd. "Oil prices are expected to stay under pressure next week if the spread of the pandemic continues to accelerate in many parts of the world," he said.
   Goldman rebaja las estimaciones de Aena para 2021 a pesar de la vacuna  2020/11/13 04:00:00 El Confidencial
Creen que el año que viene aún es pronto para pensar en una recuperación mucho mejor que antes del anuncio de Pfizer. La clave será 2022, que traería una 'nueva normalidad'
   Bourla (Pfizer) ordenó hace tres meses su polémica venta de acciones del 9-N  2020/11/13 03:30:00 La Información
El anuncio de una vacuna potencialmente eficaz contra el Covid-19 por parte de Pfizer y Biontech fue la gran noticia del pasado lunes, algo enturbiada por acusaciones falsas de insider trading.
   CGS-CIMB: Asean aviation stocks rally partly fuelled by ‘fear of missing out’  2020/11/13 03:00:00 The Sun Daily
PETALING JAYA: Although aviation counters across the Asean region have seen a jump following the positive headlines over Pfizer’s vaccine success, CGS-CIMB Research opined that it has yet to turn positive on the sector as it sees the market sentiment running too far ahead of fundamentals. It pointed out that the region’s best-performing stocks to date, Airports Corporation of Vietnam (ACV) and Airports of Thailand (AOT), were the relative laggards in the recent rally, while the worst-performing stocks rose the most. “Although airline share prices gave up some of their gains yesterday, airport stocks continued their rise, in a classic mean reversion towards cyclicals and industrials, but probably also due to investors’ fear of missing out (FOMO),” explained the research house in a report. It listed that for the two Add calls, ACV is still trading below its VND79,400 target, but Malaysia Airports Holdings Bhd (MAHB) has risen above the RM5.14 target, while its Hold calls, Singapore Airlines (SIA) and SATS Ltd is trading higher than the S$3.46 and S$3 target.
   U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis  2020/09/28 20:54:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight.1 This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for t
   Merck, Pfizer prevail in patent fight with Biogen over multiple sclerosis drug  2020/09/28 20:00:55 Reuters
A federal appeals court on Monday invalidated a Biogen Inc patent on the treatment of multiple sclerosis using a protein known as interferon-beta, a victory for Merck & Co and Pfizer Inc, which jointly market the interferon-beta-based drug Rebif.
   Atopic Dermatitis Market Size to 2026: Velite Pharmaceuticals, Galderma SA, Pfizer Inc, Fujisawa Healthcare, Inc., Dow, Regeneron Pharmaceuticals, Inc  2020/09/28 18:53:50 OpenPR
The Atopic Dermatitis Market analysis report is a competent and deep analysis of the present situation and challenges. It also makes available analysis of market size, shares, growth, segmentation, revenue projection (USD Mn), and regional study till 2026. The market
   Ron Paul: "Question 'The Science'? Go To Gulag!"  2020/09/28 18:40:00 Zero Hedge
Ron Paul: "Question 'The Science'? Go To Gulag!" Tyler Durden Mon, 09/28/2020 - 14:40 Authored by Ron Paul via The Ron Paul Institute for Peace & Prosperity, In the Soviet Union it was forbidden to dispute the wisdom of the “party line.” That’s because Marxian communism was viewed as the scientifically inevitable progression of mankind. For Marx and Lenin, the “science was settled.” Therefore anyone speaking out against “the science” of the Soviet system must be acting with malice; must actually want destruction; must want people to die. Anyone voicing opposition to the “settled science” of Marxism-Leninism soon found their voice silenced. Oftentimes permanently. Ironically, just 30 years after the “science” of Marxism-Leninism imploded for all the world to see, we are witnessing a resurgence here in the US of the idea that to question “the science” is not to seek truth or refine understanding of what appears to be conflicting evidence. No, it is to actually wish harm on one’s fellow Americans.
   Human Growth Hormone Market Size, Share, Trends, Regional Analysis and Forecast 2027 | Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Sandoz International  2020/09/28 13:34:29 OpenPR
The latest release from SMI with title Human Growth Hormone Market Research Report 2020-2027 (by Product Type, End-User/Application, and Regions/Countries) evaluates each segment of the Human Growth Hormone market in detail so that readers can be guided about future opportunities
   COVID-19 vaccine developers prepare joint safety pledge: Report  2020/09/05 00:03:09 Channel NewsAsia
Several COVID-19 vaccine developers, including Pfizer Inc, Johnson & Johnson and Moderna Inc, plan to issue a public pledge not to seek government approval until their vaccine candidates are proven to be safe and effective, the Wall Street Journal reported on Friday.
   Ex-FDA Commissioner On How Coronavirus Vaccine Approval Could Come In Stages  2020/09/04 19:19:09 Benzinga
The Trump administration is urging individual states to start working on a strategy to distribute a coronavirus vaccine by Nov. 1, but some experts are skeptical of the quick timeline, as it comes just weeks after interim study results. Early Vaccine Data Within Weeks: U.K.-based AstraZeneca plc (NYSE: AZN ) is expected to release data in mid-September that could confirm that its vaccine can prevent people from contracting the disease. Prior to a scheduled U.S. Food and Drug Administration meeting Oct. 22, similar readouts are expected from Moderna Inc (NASDAQ: MRNA ) and BioNTech's collaboration with Pfizer Inc. (NYSE: PFE ). These readouts will merely be interim results, and a final readout will likely be released sometime from the middle of November through the end of the year, Rasmus Bech Hansen, CEO of the drug trial … Full story available on Benzinga.com
   This might be the first coronavirus vaccine that stops severe COVID-19 cases  2020/09/04 19:16:34 BGR
A new chapter in the race to develop a safe and effective coronavirus vaccine has been written. An experimental vaccine was able to prevent severe illness in hamsters that were exposed to the virus four weeks after receiving the vaccine candidate. Johnson & Johnson researchers say this might be the first study that proves a vaccine can prevent severe complications like pneumonia in animal subjects. Phase 3 of the Ad26.COV2.S human trials will start in September, with the company looking to include 60,000 volunteers in the study. At least seven coronavirus vaccine candidates have now reached Phase 3 trials, which gives us hope that at least one of these drugs will be effective and safe. Three of these vaccines are made in China, one in Russia, and the other three come from Europe and the US. Russia and China have already approved their drugs for emergency use, with the former drawing plenty of criticism for the lack of scientific data that would back up the decision to push for early approval.
   'Widespread Covid vaccinations not until mid-2021'  2020/09/04 10:38:32 Economic Times India
The World Health Organization does not expect widespread vaccinations against COVID-19 until the middle of next year, a spokeswoman said on Friday, stressing the importance of rigorous checks on their effectiveness and safety.None of the candidate vaccines in advanced clinical trials so far has demonstrated a "clear signal" of efficacy at the level of at least 50% sought by the WHO, spokeswoman Margaret Harris said.Russia granted regulatory approval to a COVID-19 vaccine in August after less than two months of human testing, prompting some Western experts to question its safety and efficacy.U.S. public health officials and Pfizer Inc said on Thursday a vaccine could be ready for distribution as soon as late October. That would be just ahead of the U.S. election on Nov. 3 in which the pandemic is likely to be a major factor among voters deciding whether President Donald Trump wins a second term."We are really not expecting to see widespread vaccination until the middle of next year," Harris told a U.N. briefing in Geneva."This phase 3 must take longer because we need to see how truly protective the vaccine is and we also need to see how safe it is," she added.
   Coronavirus Vaccine update: Pfizer’s Covid-19 vaccine is in ‘very advanced stage’, final results expected in October  2020/09/04 10:13:00 The Financial Express
Coronavirus Vaccine news, update: Coronavirus vaccine by Pfizer-BioNTech is in a "very advanced stage" and the US-based drug-making company would be able to ascertain by the end of October whether the coronavirus vaccine they are developing is safe and effective, said Pharmaceutical giant Pfizer's chief executive, Dr. Albert Bourla. If the safety and the efficacy […]

 関連キーワード  (医薬品 米国株 PFE ファイザ― PFE )

 twitter  (公式ツイッターやCEOツイッターなど)

PFE動画